The inoculum effect: Fact or artifact?

[1] ANDES D, 2001, ABSTRACTS P 41 INT S

[2] Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum β-lactamases [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (11) : 626 - 635

[3] In vitro killing of parenteral beta-lactams against standard and high mocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 49 (01) : 41 - 46

[4] CRAIG WA, 2003, PROGRAMS ABSTRACTS I

[5] COMPARISON OF THE INOCULUM EFFECT OF CEFOXITIN AND OTHER CEPHALOSPORINS AND OF BETA-LACTAMASE INHIBITORS AND THEIR PENICILLIN-DERIVED COMPONENTS ON THE BACTEROIDES-FRAGILIS GROUP [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (09) : 1868 - 1874

[6] Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) : 1941 - 1947

[7] NCCLS, 2003, METH DIL ANT SUSC TE

[8] *NCCLS, 2004, PERF STAND ANT SUSC

[9] Effects of inoculum and β-lactamase activity in AmpC- and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (01) : 269 - 275

[10] Antimicrobial susceptibility of clinical isolates of Enterobacteriaceae producing complex β-lactamase patterns including extended-spectrum enzymes [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (05) : 480 - 486

[1] ANDES D, 2001, ABSTRACTS P 41 INT S

[2] Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum β-lactamases [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (11) : 626 - 635

[3] In vitro killing of parenteral beta-lactams against standard and high mocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 49 (01) : 41 - 46

[4] CRAIG WA, 2003, PROGRAMS ABSTRACTS I

[5] COMPARISON OF THE INOCULUM EFFECT OF CEFOXITIN AND OTHER CEPHALOSPORINS AND OF BETA-LACTAMASE INHIBITORS AND THEIR PENICILLIN-DERIVED COMPONENTS ON THE BACTEROIDES-FRAGILIS GROUP [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (09) : 1868 - 1874

[6] Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) : 1941 - 1947

[7] NCCLS, 2003, METH DIL ANT SUSC TE

[8] *NCCLS, 2004, PERF STAND ANT SUSC

[9] Effects of inoculum and β-lactamase activity in AmpC- and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (01) : 269 - 275

[10] Antimicrobial susceptibility of clinical isolates of Enterobacteriaceae producing complex β-lactamase patterns including extended-spectrum enzymes [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (05) : 480 - 486